Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference

Print Friendly, PDF & Email

H.C. Wainwright 25th Annual Global Investment Conference

Format: On-Demand
Available: Beginning Monday, September 11, 2023 at 7:00am ET
Webcast: https://journey.ct.events/view/002ac4ec-0d8d-4aa9-8c0f-c72b5bec025d

The Eyenovia management team will be participating in one-on-one meetings during the event. Investors interested in meeting with Eyenovia at the conference should contact their H.C. Wainwright representative.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as the ongoing late-stage development of medications in the Optejet device for presbyopia and myopia progression (partnered with Bausch+Lomb). For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
(646) 751-4363

Eyenovia Media Contact:
Norbert Lowe
Vice President, Commercial Operations